First National Bank & Trust Co. of Newtown Has $261,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

by · The Cerbat Gem

First National Bank & Trust Co. of Newtown decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 8.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,417 shares of the medical equipment provider’s stock after selling 234 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Zimmer Biomet were worth $261,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Crewe Advisors LLC purchased a new stake in Zimmer Biomet during the first quarter valued at about $31,000. J.Safra Asset Management Corp raised its holdings in shares of Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares during the period. Bangor Savings Bank acquired a new position in Zimmer Biomet in the 3rd quarter worth approximately $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet during the 2nd quarter worth approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Zimmer Biomet in the second quarter valued at $43,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 1.3 %

Shares of Zimmer Biomet stock opened at $108.69 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The company’s 50-day moving average price is $106.64 and its 200-day moving average price is $110.58. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The company has a market cap of $21.64 billion, a price-to-earnings ratio of 20.66, a PEG ratio of 2.02 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the previous year, the business posted $1.65 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet’s dividend payout ratio is 18.25%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ZBH shares. Morgan Stanley lowered their price target on Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. Oppenheimer cut their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. TD Cowen reduced their target price on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Royal Bank of Canada upped their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday. Finally, UBS Group lowered their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $124.11.

View Our Latest Research Report on ZBH

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).